Konvalinka 2006.
| Methods | Double‐blind, randomised controlled trial | |
| Participants | Elective cardiac surgery patients. All carriers. Mupirocin: 130. Placebo: 127. Only COPD was more prevalent in the mupirocin group (p<0.01) | |
| Interventions | Mupirocin or placebo. Twice daily for 7 days, before surgery. | |
| Outcomes | S. aureus infection rate. Mortality. Adverse events. Infection rate caused by other micro‐organisms than S. aureus. | |
| Notes | ||
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment? | Low risk | Adequate |
| Blinding? participants | Low risk | |
| Blinding? investigator | Low risk | |
| Blinding? outcome assessor | Low risk | |
| Blinding? data analysis | Low risk | |
| Intention to treat | Low risk | reported and confirmed |
| Loss to follow up | High risk | |